Combination strategies of immunotherapy in breast cancer
Combination strategies of immunotherapy in breast cancer
Highlights in SCLC from ESMO 2018
Safety analysis of entrectinib for NTRK fusion tumours
TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Lung highlights from ESMO 2018
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC
Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA
The standard of care and progress so far with PARP inhibitors for ovarian cancer